PL373379A1 - Bifenylokarboksyamidy podstawione N-arylopiperydyną jako inhibitory wydzielania apolipoproteiny B - Google Patents

Bifenylokarboksyamidy podstawione N-arylopiperydyną jako inhibitory wydzielania apolipoproteiny B

Info

Publication number
PL373379A1
PL373379A1 PL03373379A PL37337903A PL373379A1 PL 373379 A1 PL373379 A1 PL 373379A1 PL 03373379 A PL03373379 A PL 03373379A PL 37337903 A PL37337903 A PL 37337903A PL 373379 A1 PL373379 A1 PL 373379A1
Authority
PL
Poland
Prior art keywords
apolipoprotein
secretion
inhibitors
piperidine substituted
aryl piperidine
Prior art date
Application number
PL03373379A
Other languages
English (en)
Other versions
PL212405B1 (pl
Inventor
Lieven Meerpoel
Leo Jacobus Jozef Backx
Peter Walter Maria Roevens
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of PL373379A1 publication Critical patent/PL373379A1/pl
Publication of PL212405B1 publication Critical patent/PL212405B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL373379A 2002-08-12 2003-08-05 Zwiazek bifenylokarboksyamidowy, kompozycja farmaceutyczna oraz zastosowanie PL212405B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02078309 2002-08-12

Publications (2)

Publication Number Publication Date
PL373379A1 true PL373379A1 (pl) 2005-08-22
PL212405B1 PL212405B1 (pl) 2012-09-28

Family

ID=31896911

Family Applications (1)

Application Number Title Priority Date Filing Date
PL373379A PL212405B1 (pl) 2002-08-12 2003-08-05 Zwiazek bifenylokarboksyamidowy, kompozycja farmaceutyczna oraz zastosowanie

Country Status (31)

Country Link
US (2) US20060040989A1 (pl)
EP (1) EP1536796B1 (pl)
JP (1) JP4559856B2 (pl)
KR (1) KR101052204B1 (pl)
CN (3) CN101165052B (pl)
AR (1) AR040968A1 (pl)
AT (1) ATE385796T1 (pl)
AU (1) AU2003250215B2 (pl)
BR (1) BR0313377A (pl)
CA (1) CA2494208C (pl)
CY (1) CY1107945T1 (pl)
DE (1) DE60319097T2 (pl)
DK (1) DK1536796T3 (pl)
EA (1) EA008061B1 (pl)
EG (1) EG25699A (pl)
ES (1) ES2301873T3 (pl)
HR (1) HRP20050103B1 (pl)
IL (1) IL166795A (pl)
IS (1) IS2726B (pl)
MX (1) MXPA05001712A (pl)
MY (1) MY136632A (pl)
NO (1) NO329308B1 (pl)
NZ (1) NZ538680A (pl)
PA (1) PA8579901A1 (pl)
PL (1) PL212405B1 (pl)
PT (1) PT1536796E (pl)
SI (1) SI1536796T1 (pl)
TW (1) TWI342775B (pl)
UA (1) UA79300C2 (pl)
WO (1) WO2004017969A1 (pl)
ZA (1) ZA200501225B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83510C2 (en) * 2003-12-09 2008-07-25 Янссен Фармацевтика Н.В. N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b
FR2883000B1 (fr) * 2005-03-14 2007-06-01 Merck Sante Soc Par Actions Si Derives de trifluoromethylbenzamide et leurs utilisations en therapeutique
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
EP1948629A1 (en) 2005-10-31 2008-07-30 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
DK2666859T3 (en) 2006-04-03 2019-04-08 Roche Innovation Ct Copenhagen As PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES
EP2261333B1 (en) * 2006-04-03 2016-03-30 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
WO2008100423A1 (en) * 2007-02-09 2008-08-21 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
DK2149605T3 (da) * 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
AU2008228243B2 (en) * 2007-03-22 2014-05-15 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-B100 expression
WO2009027527A2 (en) * 2007-08-30 2009-03-05 Santaris Pharma A/S Rna antagonist compounds for the modulation of fabp4/ap2
ES2360929T3 (es) * 2007-09-20 2011-06-10 Amgen Inc. Derivados del ácido 1-(4-(4-bencilbenzamido)-bencil)azetidin-3-carboxílico y compuestos relacionados como moduladores del receptor s1p para el tratamiento de trastornos inmunitarios.
ES2463665T3 (es) 2007-10-04 2014-05-28 Stella Aps Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
EP2268811A1 (en) * 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
US8492357B2 (en) 2008-08-01 2013-07-23 Santaris Pharma A/S Micro-RNA mediated modulation of colony stimulating factors
JP5773535B2 (ja) * 2009-04-24 2015-09-02 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ インターフェロンに非応答性のｈｃｖ患者の治療のための医薬組成物
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
AU2014300981B2 (en) 2013-06-27 2017-08-10 Ricc A/S Antisense oligomers and conjugates targeting PCSK9
CA2951917C (en) 2014-06-16 2019-09-24 Johnson Matthey Public Limited Company Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4847271A (en) * 1986-01-27 1989-07-11 Merck & Co., Inc. Antihypercholesterolemic β-lactones
US5041432A (en) * 1987-01-30 1991-08-20 E. I. Du Pont De Nemours And Company Steroid derivatives useful as hypocholesterolemics
US5064856A (en) * 1989-07-31 1991-11-12 Merck & Co., Inc. Novel hmg-coa synthase inhibitors
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
EP0618803A4 (en) * 1991-12-19 1995-03-22 Southwest Found Biomed Res POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS.
DE69332792T2 (de) 1992-04-20 2004-01-15 Takeda Chemical Industries Ltd 4,1-Benzoxazepinderivate als Squalen-Synthetase Inhibitoren und ihre Verwendung zur Behandlung von Hypercholesterämie und als Fungizide
AU678503B2 (en) 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
AU3577995A (en) 1994-10-04 1996-04-26 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
US5510379A (en) * 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
GB9504066D0 (en) 1995-03-01 1995-04-19 Pharmacia Spa Phosphate derivatives of ureas and thioureas
WO1998047875A1 (en) * 1997-04-18 1998-10-29 Pfizer Inc. Process and intermediates for the preparation of 4'-trifluoromethyl-biphenyl-2-carboxylic acid (1,2,3,4-tetrahydro-isoquinolin-6-yl)-amide
GB9826412D0 (en) * 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
GB0013383D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0013378D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
JO2409B1 (en) * 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
JO2390B1 (en) * 2001-04-06 2007-06-17 شركة جانسين فارماسوتيكا ان. في Diphenylcarboxamides act as lipid-lowering agents
CN1233648C (zh) * 2001-06-27 2005-12-28 尔艾斯特公司 Salen催化剂、催化剂的制备和通过使用催化剂制备手性化合物的方法
GB0129015D0 (en) * 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
CA2494208A1 (en) 2004-03-04
NZ538680A (en) 2006-01-27
PT1536796E (pt) 2008-05-13
KR101052204B1 (ko) 2011-07-29
WO2004017969A1 (en) 2004-03-04
SI1536796T1 (sl) 2008-08-31
AU2003250215A1 (en) 2004-03-11
ES2301873T3 (es) 2008-07-01
CN100366252C (zh) 2008-02-06
PL212405B1 (pl) 2012-09-28
NO20050563L (no) 2005-01-31
CN101165053A (zh) 2008-04-23
EA200500348A1 (ru) 2005-08-25
US20060040989A1 (en) 2006-02-23
IL166795A0 (en) 2006-01-15
AU2003250215B2 (en) 2009-01-22
IS2726B (is) 2011-03-15
HRP20050103B1 (hr) 2013-09-30
CN101165052A (zh) 2008-04-23
EG25699A (en) 2012-05-22
CY1107945T1 (el) 2013-09-04
NO329308B1 (no) 2010-09-27
US20090156623A1 (en) 2009-06-18
ATE385796T1 (de) 2008-03-15
BR0313377A (pt) 2005-07-12
CN101165052B (zh) 2012-04-18
DE60319097T2 (de) 2009-06-04
EP1536796A1 (en) 2005-06-08
EA008061B1 (ru) 2007-02-27
UA79300C2 (en) 2007-06-11
TW200412954A (en) 2004-08-01
CN1674900A (zh) 2005-09-28
DK1536796T3 (da) 2008-06-09
AR040968A1 (es) 2005-04-27
MY136632A (en) 2008-11-28
CA2494208C (en) 2011-05-10
MXPA05001712A (es) 2005-04-19
PA8579901A1 (es) 2005-03-03
IL166795A (en) 2010-11-30
TWI342775B (en) 2011-06-01
HK1083451A1 (en) 2006-07-07
KR20050026483A (ko) 2005-03-15
IS7622A (is) 2004-12-29
ZA200501225B (en) 2006-07-26
HRP20050103A2 (en) 2006-09-30
JP4559856B2 (ja) 2010-10-13
JP2006500371A (ja) 2006-01-05
US8258304B2 (en) 2012-09-04
DE60319097D1 (de) 2008-03-27
EP1536796B1 (en) 2008-02-13

Similar Documents

Publication Publication Date Title
SI1536796T1 (sl) Bifenilkarboksamidi, substituirani z N-aril piperidinom, kot inhibitorji izločanja apolipoproteina B
EP1549316A4 (en) HAMMER OF TFGbeta
AU2002344567A1 (en) Heterocyclic amide compounds as apolipoprotein b inhibitors
PL375389A1 (pl) Nowe inhibitory kinaz
AU2003278088A1 (en) Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
IL165887A0 (en) Novel tetrahydropyridine derivatives as renin inhibitors
EP1613595A4 (en) NOVEL COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN KINASE
SI1545226T1 (sl) Postopek frakcioniranja mleäśnih sestavkov
AU2003271566A8 (en) Pyrrolopyrazines as kinase inhibitors
AU2003261434A8 (en) Iminothiazolidinones as inhibitors of hcv replication
IL163909A0 (en) Methods of inducing terminal differentiation
SI1562902T1 (sl) 2-piridonski derivati kot inhibitorji nevtrofilneelastaze
AU2003217105A1 (en) Novel of cytokine inhibitors
AU2003232848A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
EP1638565A4 (en) SUBSTITUTED PIPERIDINE COMPOUNDS AND METHOD OF USE THEREOF
ZA200409686B (en) Bicyclic 6-aklylidene-penems as ?-lactamases inhibitors
AU2003299901A8 (en) Thrombin inhibitors
IL165115A0 (en) Novel crystalline forms of gatifloxacin
AU2003295638A8 (en) Novel inhibitors of beta-lactamase
GB0223276D0 (en) Cladding of rails
IL166592A0 (en) Novel crystalline forms of gatifloxacin
AU2003215298A1 (en) Alpha1beta1 antagonists for treatment of atherosclerosis
AU2003299137A8 (en) Inhibition of metallo-beta-lactamase
IL161521A0 (en) N-formyl derivatives of paroxetine
PL376796A1 (pl) Sposób wytwarzania inhibitorów fosfodiesterazy-4